Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results.
Alopecia
Breast cancer
Hair loss
Scalp cooling
Taxane
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
02
12
2020
accepted:
15
12
2020
pubmed:
17
1
2021
medline:
24
6
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Recent evidence supports the efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer treatments. However, efficacy largely varies between treatment regimens. The aim of this study was to explore the patient- and nurse-reported results of scalp cooling in terms of hair loss and need for a wig/head cover in patients with breast cancer treated with 3-weekly docetaxel 75 mg/m We studied nurse-reported efficacy as noted in the electronic patient files of 85 patients treated with docetaxel 75 mg/m Nurse- and patient-reported data showed that scalp cooling was successful (i.e., hair loss < 50%) in 47.1 and 44.9% of patients, respectively, and 55% of patients were (very) satisfied with the result of scalp cooling. Scalp cooling was perceived as (very) uncomfortable in 36.2% of patients. Regarding hair status one year after treatment, 47 patients (55.3%) reported no changes compared to their hair status before treatment. Scalp cooling is successful in preventing severe chemotherapy-induced alopecia in almost half of the patients with breast cancer treated with docetaxel 75 mg/m
Identifiants
pubmed: 33452953
doi: 10.1007/s10549-020-06063-w
pii: 10.1007/s10549-020-06063-w
doi:
Substances chimiques
Docetaxel
15H5577CQD
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
715-722Références
Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH et al (2014) Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology 23(10):1103–1110
doi: 10.1002/pon.3531
Frith H, Harcourt D, Fussell A (2007) Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs 11(5):385–391
doi: 10.1016/j.ejon.2007.03.002
Harcourt D, Frith H (2008) Women’s experiences of an altered appearance during chemotherapy: an indication of cancer status. J Health Psychol 13(5):597–606
doi: 10.1177/1359105308090932
Shaw J, Baylock B, O’Reilly A, Winstanley J, Pugliano L, Andrews K, Boyle F (2016) Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer. Support Care Cancer 24(9):3813–3820
doi: 10.1007/s00520-016-3206-2
Rugo HS, Melin SA, Voigt J (2017) Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 163(2):199–205
doi: 10.1007/s10549-017-4185-9
Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 317(6):596–605
doi: 10.1001/jama.2016.20939
Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bageman E, D’Agostino RB Jr et al (2017) Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 317(6):606–614
doi: 10.1001/jama.2016.21038
Smetanay K, Junio P, Feisst M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J et al (2019) COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat 173(1):135–143
doi: 10.1007/s10549-018-4983-8
Gianotti E, Razzini G, Bini M, Crivellaro C, Righi A, Darecchio S, Lui S, Basirico ML, Cocconi S, Cagossi K et al (2019) Scalp cooling in daily clinical practice for breast cancer patients undergoing curative chemotherapy: a multicenter interventional study. Asia Pac J Oncol Nurs 6(3):277–282
doi: 10.4103/apjon.apjon_4_19
van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients: results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504
doi: 10.3109/0284186X.2012.658966
Komen MM, Breed WP, Smorenburg CH, van der Ploeg T, Goey SH, van der Hoeven JJ, Nortier JW, van den Hurk CJ (2016) Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 24(6):2735–2741
doi: 10.1007/s00520-016-3084-7
van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255–3260
doi: 10.1007/s00520-012-1465-0
Bitto FF, Konig A, Phan-Brehm T, Vallbracht T, Koch JG, Schinkothe T, Wolfgarten M, Mahner S, Harbeck N, Wurstlein R (2020) EVA-scalp: evaluation of patient satisfaction with a scalp cooling device to prevent chemotherapy-induced alopecia in breast cancer patients. Breast Care 15(2):171–177
doi: 10.1159/000501393
Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18(7):885–891
doi: 10.1634/theoncologist.2012-0332
Komen MMC, van den Hurk CJG, Nortier JWR, van der Ploeg T, Nieboer P, van der Hoeven JJM, Smorenburg CH (2019) Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. Support Care Cancer 27(5):1919–1925
doi: 10.1007/s00520-018-4432-6
van den Hurk C, Keizer-Heldens P, Raats I, Hoeijmakers K, Mols F (2019) Improving information provision on chemotherapy-induced alopecia and scalp cooling: a comprehensive approach including a website and web-based decision tool. Asia Pac J Oncol Nurs 6(4):336–342
doi: 10.4103/apjon.apjon_19_19
Tallon B, Blanchard E, Goldberg LJ (2010) Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 63(2):333–336
doi: 10.1016/j.jaad.2009.06.063
Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, Cho J, Goldfarb S, Modi S, Gajria D et al (2019) Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol 155(6):724–728
doi: 10.1001/jamadermatol.2018.5071
Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH et al (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414–420
doi: 10.1634/theoncologist.2018-0184
Martin M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, Gonzalez Del Val R et al (2018) Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat 171(3):627–634
doi: 10.1007/s10549-018-4855-2